KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $731.8 million.

  • Amneal Pharmaceuticals' Accounts Payables rose 905.1% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year increase of 905.1%. This contributed to the annual value of $735.4 million for FY2024, which is 3755.42% up from last year.
  • Amneal Pharmaceuticals' Accounts Payables amounted to $731.8 million in Q3 2025, which was up 905.1% from $666.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Accounts Payables ranged from a high of $735.4 million in Q4 2024 and a low of $467.4 million during Q1 2023
  • Its 5-year average for Accounts Payables is $586.3 million, with a median of $561.7 million in 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Accounts Payables plummeted by 1414.07% in 2021 and then soared by 3755.42% in 2024.
  • Amneal Pharmaceuticals' Accounts Payables (Quarter) stood at $525.3 million in 2021, then increased by 2.45% to $538.2 million in 2022, then dropped by 0.66% to $534.7 million in 2023, then skyrocketed by 37.55% to $735.4 million in 2024, then decreased by 0.49% to $731.8 million in 2025.
  • Its last three reported values are $731.8 million in Q3 2025, $666.8 million for Q2 2025, and $628.6 million during Q1 2025.